Published online before print December 16, 2005, doi:10.1212/01.wnl.0000192107.17175.39)
NEUROLOGY 2006;66:S69-S73
© 2006 American Academy of Neurology
Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments
Kulandaivelu S. Vetrivel, PhD and
Gopal Thinakaran, PhD
From the Department of Neurobiology, Pharmacology and Physiology, University of Chicago, Chicago, IL.
Address correspondence and reprint requests to Dr. Gopal Thinakaran, Department of Neurobiology, Pharmacology and Physiology, University of Chicago, Chicago, IL 60637; e-mail: gopal{at}uchicago.edu
Trafficking and proteolytic processing of amyloid precursor protein (APP) have been the focus of numerous investigations in the past two decades, since the identification of Aβ as the principal component of brain senile plaques and the cloning of APP cDNA. Tremendous progress has been made in the recent past toward the characterization of β- and  -secretases. Here, we review the salient features of Alzheimer disease amyloidogenesis, and discuss the current knowledge on APP trafficking and amyloidogenic processing of APP in intracellular membrane compartments and microdomains.
This article was previously published in electronic format as an Expedited E-Pub at www.neurology.org.
Supported by grants from the National Institutes of Health, Alzheimer’s Association, and American Health Assistance Foundation (G.T.), and a fellowship from the Alzheimer Disease Research Fund of Illinois Department of Public Health (K.S.V.).
Disclosure: The authors report no conflicts of interest.
Received June 22, 2005. Accepted in final form October 14, 2005.
This article has been cited by other articles:
|
|
|
|
 
S. A Greenberg
How citation distortions create unfounded authority: analysis of a citation network
BMJ,
July 23, 2009;
339(jul20_3):
b2680 - b2680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Olanow, M. B. Stern, and K. Sethi
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Neurology,
May 26, 2009;
72(21_Supplement_4):
S1 - S136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Lang
When and how should treatment be started in Parkinson disease?
Neurology,
February 17, 2009;
72(7_Supplement_2):
S39 - S43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Olanow
Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
Neurology,
February 17, 2009;
72(7_Supplement_2):
S59 - S64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Vetrivel, X. Meckler, Y. Chen, P. D. Nguyen, N. G. Seidah, R. Vassar, P. C. Wong, M. Fukata, M. Z. Kounnas, and G. Thinakaran
Alzheimer Disease A{beta} Production in the Absence of S-Palmitoylation-dependent Targeting of BACE1 to Lipid Rafts
J. Biol. Chem.,
February 6, 2009;
284(6):
3793 - 3803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Vale
Current Management of the Cognitive Dysfunction in Parkinson's Disease: How Far Have We Come?
Exp Biol Med,
August 1, 2008;
233(8):
941 - 951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Schneider, L. Rajendran, M. Honsho, M. Gralle, G. Donnert, F. Wouters, S. W. Hell, and M. Simons
Flotillin-Dependent Clustering of the Amyloid Precursor Protein Regulates Its Endocytosis and Amyloidogenic Processing in Neurons
J. Neurosci.,
March 12, 2008;
28(11):
2874 - 2882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Tate and P. M. Mathews
Targeting the Role of the Endosome in the Pathophysiology of Alzheimer's Disease: A Strategy for Treatment
Sci. Aging Knowl. Environ.,
June 28, 2006;
2006(10):
re2 - re2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Finch
A perspective on sporadic inclusion-body myositis: The role of aging and inflammatory processes
Neurology,
January 24, 2006;
66(1_suppl_1):
S1 - S6.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
